Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tafamidis for transthyretin amyloidosis.

Drugs of today (Barcelona, Spain : 1998) - 1 May 2012

de Lartigue J

Abstract excerpt

Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. Pathogenic mutations in the transthyretin (TTR) protein lead to destabilization of its tetrameric structure and subsequent formation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to FAP gene
Share to TTR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Mutation

Share to Neuroprotective Agents

Share to Prealbumin

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 22645721
DOI: 10.1358/dot.2012.48.5.1808486

Genes

TTR
FAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tafamidis for transthyretin amyloidosis.PMID 22645721Read ↗

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.Semantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.Semantic proximity Read ↗

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.Semantic proximity Read ↗

Tafamidis (Vyndaqel): a light for FAP patients.Semantic proximity Read ↗

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.Semantic proximity Read ↗

TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathiesSemantic proximity Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.Semantic proximity Read ↗

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Semantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.